Value Add VC tracks 2 companies Lilly Asia Ventures has invested in and 2 venture rounds it took part in (0 as lead).
Lilly Asia Ventures key facts (as of )
| Fact | Value | Source |
|---|---|---|
| Type | Venture capital firm | Value Add VC classification |
| Venture rounds tracked | 2 (led 0, joined 2) 2 in the last 12 months | Recent deals table on this page (each round cites its source) |
| Portfolio companies tracked | 2 | Portfolio list on this page |
Recent deals we track
2Track record: led 0 and participated in 2 of 2 tracked venture rounds · 2 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Stairmed | late-stage | Participated | $192.5M | — | TencentunverifiedAlibabaunverifiedCATLunverifiedOrbiMed AdvisorsunverifiedQiming Venture PartnersunverifiedLilly Asia VenturesunverifiedGeely Capital | Dealroom |
| Aug 13, 2026 | Khartis Therapeutics | Series B | Participated | $50M | — | Foresite CapitalunverifiedLilly Asia VenturesunverifiedNextech InvestunverifiedForge Life Science Partners | Pulse story |
Is something wrong on this page?
We track Lilly Asia Ventures but have little verified detail yet.
At a glance
Lilly Asia Ventures appears in 2 funding rounds tracked by ValueAddVC since 2026. Its most recent tracked deal was Stairmed's $192.5M round (Oct 30, 2026).
Portfolio
2 totalSector / Stage Activity
Co-Investors
7Value Add Research
Latest Pulse
- Oct 30, 2026Stairmed Raises $192.5M, Claims More Implants Than NeuralinkShanghai implant maker Stairmed raised about $192.5 million in a late-stage round backed by Tencent and Alibaba, and says it has placed 42 long-term brain-computer implants versus Neuralink's 27.→
- Sep 25, 2026ADARx Prices $446M IPO, Debuts As ADRXADARx Pharmaceuticals priced an upsized $446 million IPO at $17 a share and began trading on the Nasdaq as ADRX, joining the fall biotech IPO window alongside its existing AbbVie drug partnership.→
- Aug 13, 2026Khartis Emerges From Stealth With $95M for a Thyroid PillKhartis Therapeutics emerged from stealth with $95 million in total funding, including a new $50 million Series B, to develop an oral alternative to injectable treatments for thyroid eye disease.→
Lilly Asia Ventures FAQ
What stage does Lilly Asia Ventures invest at?
In the rounds Value Add VC tracks, Lilly Asia Ventures' deals were most often late-stage (1) and Series B (1).
What companies has Lilly Asia Ventures backed?
Companies Value Add VC tracks as Lilly Asia Ventures investments include Stairmed and Khartis Therapeutics.
Who does Lilly Asia Ventures co-invest with most?
In the rounds Value Add tracks, Lilly Asia Ventures most often invests alongside Alibaba (1 shared deal), CATL (1 shared deal), Foresite Capital (1 shared deal), Nextech Invest (1 shared deal), OrbiMed Advisors (1 shared deal).
Sources & methodologyshow
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.